Unicycive Under Investigation for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Globenewswire
- FDA Response Letter: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter (CRL) regarding its resubmitted New Drug Application for kidney disease therapy, indicating the same third-party manufacturing deficiencies identified in the prior June 2025 CRL, highlighting significant hurdles in the drug approval process.
- Stock Price Plunge: Following this announcement, Unicycive's stock price fell from $7.70 per share on June 29, 2026, to $4.69 on June 30, representing a 39% decline, reflecting strong investor concerns about the company's future prospects.
- Legal Investigation Initiated: Kirby McInerney LLP reminds investors of its ongoing investigation into potential violations of federal securities laws by Unicycive and its senior management, with no lawsuits filed yet, indicating possible reputational and shareholder equity impacts for the company.
- Investor Rights Protection: The law firm encourages investors who purchased or acquired Unicycive securities to contact them to discuss their rights, emphasizing that protecting investor interests will be a focal point as the company faces legal challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.430
Low
21.00
Averages
35.80
High
60.00
Current: 5.430
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Unicycive Under Investigation for Securities Violations
- FDA Response Letter: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter (CRL) regarding its resubmitted New Drug Application for kidney disease therapy, indicating the same third-party manufacturing deficiencies identified in the prior June 2025 CRL, highlighting significant hurdles in the drug approval process.
- Stock Price Plunge: Following this announcement, Unicycive's stock price fell from $7.70 per share on June 29, 2026, to $4.69 on June 30, representing a 39% decline, reflecting strong investor concerns about the company's future prospects.
- Legal Investigation Initiated: Kirby McInerney LLP reminds investors of its ongoing investigation into potential violations of federal securities laws by Unicycive and its senior management, with no lawsuits filed yet, indicating possible reputational and shareholder equity impacts for the company.
- Investor Rights Protection: The law firm encourages investors who purchased or acquired Unicycive securities to contact them to discuss their rights, emphasizing that protecting investor interests will be a focal point as the company faces legal challenges.
See More
Unicycive Faces Investor Lawsuit Investigation
- FDA Response Letter: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter regarding its resubmitted New Drug Application for kidney disease therapy, indicating ongoing third-party manufacturing deficiencies that hindered product approval.
- Significant Stock Decline: Following this announcement, Unicycive's stock price plummeted from $7.70 per share on June 29 to $4.69 on June 30, representing a 39% drop, which directly impacted investors' asset values and raised concerns about the company's future.
- Legal Investigation Initiated: The law firm Bragar Eagel & Squire is investigating whether Unicycive has violated federal securities laws, encouraging affected investors to reach out for legal options, highlighting potential legal risks and a decline in investor confidence.
- Investor Rights Protection: The firm offers no-cost legal consultations to assist long-term shareholders in understanding their rights and potential claims, reflecting the importance of safeguarding investor interests and the necessity for protective measures.
See More
Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
- Investigation Background: Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations, specifically whether the company made false or misleading statements to investors or failed to disclose material information regarding the FDA's review of its OLC New Drug Application.
- FDA Response: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter for its resubmitted OLC NDA, citing the same third-party manufacturing deficiencies identified in a prior Complete Response Letter from June 2025, which led to a decline in the company's stock price.
- Investor Rights: Any investor who purchased Unicycive stock and experienced losses is encouraged to contact Block & Leviton to learn how they might recover those losses, demonstrating the firm's commitment to protecting investor interests.
- Whistleblower Program: Block & Leviton invites whistleblowers with non-public information to assist in the investigation, stating that those who provide original information to the SEC may receive rewards of up to 30% of any successful recovery, thereby enhancing the appeal for investor cooperation.
See More
Unicycive's Drug Faces Second FDA Rejection
- FDA Rejection: Unicycive's drug oxylanthanum carbonate (OLC) faced a second rejection from the FDA due to third-party manufacturing deficiencies rather than clinical safety or efficacy issues, resulting in a 39% drop in stock price in a single day.
- Analysts Maintain Ratings: Despite the FDA's rejection, both B. Riley and H.C. Wainwright maintained their 'Buy' ratings on UNCY, with B. Riley setting a price target of $22 and H.C. Wainwright lowering it to $15, reflecting confidence in the company's long-term commercial prospects.
- Active FDA Engagement: Unicycive stated it is in active discussions with the FDA, optimistic about a successful inspection of the third-party manufacturer and plans to expeditiously resubmit the New Drug Application (NDA), indicating continued confidence in the drug's efficacy and safety.
- Retail Sentiment Optimistic: Despite the stock's decline, retail investor sentiment on Stocktwits remains in the 'extremely bullish' territory, with some users expressing optimism about eventual drug approval, highlighting market expectations for the company's future.
See More
Unicycive Therapeutics Shares Plunge 37% After FDA Response
- FDA Complete Response Letter: Unicycive Therapeutics announced it received a Complete Response Letter from the FDA regarding its resubmitted NDA, resulting in a ~37% drop in stock price during Tuesday afternoon trading, indicating significant setbacks in the drug development for treating hyperphosphatemia in chronic kidney disease patients.
- Manufacturing Issues Impact: This response letter is linked to another Complete Response Letter received in June 2025 concerning manufacturing issues at a third-party site, highlighting ongoing challenges in production compliance that could affect the company's competitive position in the market.
- Reinspection Failure: The FDA was unable to re-inspect the manufacturing site by the action date of June 26, indicating a lack of confidence from regulators in the facility, which may lead to further delays and uncertainties impacting the company's future product launch plans.
- Intensifying Market Competition: Unicycive CEO Shalabh Gupta mentioned in a recent interview that despite these challenges, OLC aims to distinguish itself in the crowded hyperphosphatemia market, reflecting the company's optimistic outlook on its product's market potential despite current regulatory hurdles.
See More
Unicycive Therapeutics Under Investigation Following FDA Response, Stock Declines
- FDA Response Impact: On June 30, 2026, Unicycive Therapeutics announced that the FDA issued a second Complete Response Letter regarding its resubmitted OLC NDA, indicating unresolved third-party manufacturing deficiencies, which led to a decline in stock price and investor confidence.
- Investigation Initiated: Johnson Fistel, PLLP is investigating whether Unicycive made false or misleading statements or failed to disclose material information related to the FDA review process, potentially affecting the recoverability of investor losses.
- Investor Losses: Investors who suffered losses after purchasing Unicycive securities are encouraged to contact Johnson Fistel for more information about the investigation, highlighting the firm's commitment to protecting investor rights and possibly leading to further legal actions.
- Ongoing Regulatory Scrutiny: Unicycive disclosed that the FDA has not yet inspected its third-party manufacturer, and this revelation may exacerbate market concerns regarding the company's future compliance, impacting its long-term strategic development.
See More
Unicycive Under Investigation for Securities Violations
- FDA Response Letter: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter (CRL) regarding its resubmitted New Drug Application for kidney disease therapy, indicating the same third-party manufacturing deficiencies identified in the prior June 2025 CRL, highlighting significant hurdles in the drug approval process.
- Stock Price Plunge: Following this announcement, Unicycive's stock price fell from $7.70 per share on June 29, 2026, to $4.69 on June 30, representing a 39% decline, reflecting strong investor concerns about the company's future prospects.
- Legal Investigation Initiated: Kirby McInerney LLP reminds investors of its ongoing investigation into potential violations of federal securities laws by Unicycive and its senior management, with no lawsuits filed yet, indicating possible reputational and shareholder equity impacts for the company.
- Investor Rights Protection: The law firm encourages investors who purchased or acquired Unicycive securities to contact them to discuss their rights, emphasizing that protecting investor interests will be a focal point as the company faces legal challenges.
See More
Unicycive Faces Investor Lawsuit Investigation
- FDA Response Letter: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter regarding its resubmitted New Drug Application for kidney disease therapy, indicating ongoing third-party manufacturing deficiencies that hindered product approval.
- Significant Stock Decline: Following this announcement, Unicycive's stock price plummeted from $7.70 per share on June 29 to $4.69 on June 30, representing a 39% drop, which directly impacted investors' asset values and raised concerns about the company's future.
- Legal Investigation Initiated: The law firm Bragar Eagel & Squire is investigating whether Unicycive has violated federal securities laws, encouraging affected investors to reach out for legal options, highlighting potential legal risks and a decline in investor confidence.
- Investor Rights Protection: The firm offers no-cost legal consultations to assist long-term shareholders in understanding their rights and potential claims, reflecting the importance of safeguarding investor interests and the necessity for protective measures.
See More
Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
- Investigation Background: Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations, specifically whether the company made false or misleading statements to investors or failed to disclose material information regarding the FDA's review of its OLC New Drug Application.
- FDA Response: On June 30, 2026, Unicycive announced that the FDA issued a second Complete Response Letter for its resubmitted OLC NDA, citing the same third-party manufacturing deficiencies identified in a prior Complete Response Letter from June 2025, which led to a decline in the company's stock price.
- Investor Rights: Any investor who purchased Unicycive stock and experienced losses is encouraged to contact Block & Leviton to learn how they might recover those losses, demonstrating the firm's commitment to protecting investor interests.
- Whistleblower Program: Block & Leviton invites whistleblowers with non-public information to assist in the investigation, stating that those who provide original information to the SEC may receive rewards of up to 30% of any successful recovery, thereby enhancing the appeal for investor cooperation.
See More
Unicycive's Drug Faces Second FDA Rejection
- FDA Rejection: Unicycive's drug oxylanthanum carbonate (OLC) faced a second rejection from the FDA due to third-party manufacturing deficiencies rather than clinical safety or efficacy issues, resulting in a 39% drop in stock price in a single day.
- Analysts Maintain Ratings: Despite the FDA's rejection, both B. Riley and H.C. Wainwright maintained their 'Buy' ratings on UNCY, with B. Riley setting a price target of $22 and H.C. Wainwright lowering it to $15, reflecting confidence in the company's long-term commercial prospects.
- Active FDA Engagement: Unicycive stated it is in active discussions with the FDA, optimistic about a successful inspection of the third-party manufacturer and plans to expeditiously resubmit the New Drug Application (NDA), indicating continued confidence in the drug's efficacy and safety.
- Retail Sentiment Optimistic: Despite the stock's decline, retail investor sentiment on Stocktwits remains in the 'extremely bullish' territory, with some users expressing optimism about eventual drug approval, highlighting market expectations for the company's future.
See More
Unicycive Therapeutics Shares Plunge 37% After FDA Response
- FDA Complete Response Letter: Unicycive Therapeutics announced it received a Complete Response Letter from the FDA regarding its resubmitted NDA, resulting in a ~37% drop in stock price during Tuesday afternoon trading, indicating significant setbacks in the drug development for treating hyperphosphatemia in chronic kidney disease patients.
- Manufacturing Issues Impact: This response letter is linked to another Complete Response Letter received in June 2025 concerning manufacturing issues at a third-party site, highlighting ongoing challenges in production compliance that could affect the company's competitive position in the market.
- Reinspection Failure: The FDA was unable to re-inspect the manufacturing site by the action date of June 26, indicating a lack of confidence from regulators in the facility, which may lead to further delays and uncertainties impacting the company's future product launch plans.
- Intensifying Market Competition: Unicycive CEO Shalabh Gupta mentioned in a recent interview that despite these challenges, OLC aims to distinguish itself in the crowded hyperphosphatemia market, reflecting the company's optimistic outlook on its product's market potential despite current regulatory hurdles.
See More
Unicycive Therapeutics Under Investigation Following FDA Response, Stock Declines
- FDA Response Impact: On June 30, 2026, Unicycive Therapeutics announced that the FDA issued a second Complete Response Letter regarding its resubmitted OLC NDA, indicating unresolved third-party manufacturing deficiencies, which led to a decline in stock price and investor confidence.
- Investigation Initiated: Johnson Fistel, PLLP is investigating whether Unicycive made false or misleading statements or failed to disclose material information related to the FDA review process, potentially affecting the recoverability of investor losses.
- Investor Losses: Investors who suffered losses after purchasing Unicycive securities are encouraged to contact Johnson Fistel for more information about the investigation, highlighting the firm's commitment to protecting investor rights and possibly leading to further legal actions.
- Ongoing Regulatory Scrutiny: Unicycive disclosed that the FDA has not yet inspected its third-party manufacturer, and this revelation may exacerbate market concerns regarding the company's future compliance, impacting its long-term strategic development.
See More
